What is Techcyte?
Techcyte operates at the intersection of healthcare technology and artificial intelligence, providing sophisticated software platforms designed to digitize and analyze medical samples. The company's core competency lies in its ability to process blood, tissue, and cytology slides with high precision, effectively reducing the manual burden on pathologists and laboratory technicians. By integrating machine learning into standard diagnostic workflows, Techcyte enhances both the accuracy and the throughput of modern laboratory systems. Its market position is bolstered by strategic partnerships with industry leaders, allowing the firm to scale its diagnostic capabilities across global healthcare networks and specialized veterinary practices.
How much funding has Techcyte raised?
Techcyte has raised a total of $40.5M across 4 funding rounds:
Private Equity
$4.3M
Debt
$150K
Unspecified
$21M
Unspecified
$15M
Private Equity (2018): $4.3M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Unspecified (2021): $21M supported by Zoetis and ARUP Laboratories
Unspecified (2026): $15M featuring Van Tuyl Companies
Key Investors in Techcyte
Zoetis
Zoetis is a global leader in animal health, specializing in the discovery, development, and commercialization of vaccines and diagnostic products for both livestock and companion animals.
ARUP Laboratories
ARUP Laboratories is a premier national reference laboratory and a nonprofit enterprise of the University of Utah, renowned for its extensive expertise in clinical pathology and diagnostic testing.
Van Tuyl Companies
Van Tuyl Companies is a Scottsdale-based investment firm with a diverse portfolio, known for its commitment to community philanthropy and strategic business development.
What's next for Techcyte?
With the successful closure of this major enterprise-level funding round, Techcyte is well-positioned to accelerate its product development roadmap and expand its footprint in the global digital pathology market. The strategic capital will likely be deployed to enhance the robustness of its AI algorithms, broaden its diagnostic portfolio, and strengthen its commercial infrastructure. As the healthcare industry increasingly shifts toward automated, data-centric diagnostic models, Techcyte is poised to capitalize on the growing demand for high-efficiency, scalable pathology solutions that improve patient outcomes and operational productivity in clinical settings.
See full Techcyte company page
